Retrieve available abstracts of 8 articles: HTML format
Single Articles
September 2024
PERROTT SL, Kar SP Polygenic risk scores for genomics and population screening.
Lancet. 2024;404:935-936. PubMed
March 2024
NARUSE M, Young WF Jr Targeted molecular medicine: advances in the treatment of metastatic
phaeochromocytoma and paraganglioma.
Lancet. 2024;403:1001-1003. PubMed
February 2024
TURNBULL C, Firth HV, Wilkie AOM, Newman W, et al Population screening requires robust evidence-genomics is no exception.
Lancet. 2024;403:583-586. PubMed
July 2023
THE LANCET Genomic newborn screening: current concerns and challenges.
Lancet. 2023;402:265. PubMed
June 2023
SWEN JJ, Manson LEN, Bohringer S, Pirmohamed M, et al The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors'
reply.
Lancet. 2023;401:1851-1852. PubMed
VAN DER LINDEN L The PREPARE study: benefits of pharmacogenetic testing are unclear.
Lancet. 2023;401:1851. PubMed
ROGERS A, Mackenzie IS, MacDonald TM, Doney ASF, et al The PREPARE study: benefits of pharmacogenetic testing are unclear.
Lancet. 2023;401:1850. PubMed
CURTIS D The PREPARE study: benefits of pharmacogenetic testing are unclear.
Lancet. 2023;401:1850-1851. PubMed